Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia.
Comorbidity
Epidemiology
Linked health data
Outcome
Systemic juvenile arthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
06
02
2023
accepted:
18
03
2023
medline:
17
5
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Systemic juvenile idiopathic arthritis (S-JIA) is a rare but potentially life threatening autoinflammatory condition of childhood. Given the limited data on S-JIA from the Australasian region, we investigated the epidemiological characteristics and long-term disease outcome in S-JIA. All hospitalised patients under the age of 16 years registered with ICD-10-AM code M08.2 in in the period 1999-2014 were identified in longitudinally linked administrative health data across all Western Australian (WA) hospitals. Incidence and point prevalence estimate were per 100,000 population with Poisson regression to analyse the incidence trend. Readmissions with S-JIA as primary diagnosis were considered flares with rates for flare and other complication reported per 100 person years with 95% confidence intervals (CI). Annual S-JIA incidence was 0.61/100,000 (CI 0.28-1.25) (46 incident cases, 71.7% girls, median age 6.5 years) and stable over time as S-JIA point prevalence reached 7.15/100,000 (CI 5.29-7.45) at the end of study. Most incident cases were diagnosed in winter and spring, but documented preceding infections were rare. During a median follow-up of 8 years, disease flares occurred in 24% of patients with higher flares rate in boys (58.3; CI 44.5-74.9) than girls (14.7; CI 9.9-20.9). No deaths occurred and arthroplasty was the main, but uncommon S-JIA complication (4%). However, readmission (86.3; CI 76.4-97.2) and ED visit (73.3; CI 64.2-83.4) rates for illnesses other than S-JIA were substantial. S-JIA is as rare in WA as in other regions and while s-JIA incurred no deaths in the era of biologics, it associated with a significant long-term burden of (co-) morbidity.
Identifiants
pubmed: 36988674
doi: 10.1007/s00296-023-05318-1
pii: 10.1007/s00296-023-05318-1
pmc: PMC10185593
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1357-1362Subventions
Organisme : Arthritis Australia
ID : PG21
Informations de copyright
© 2023. The Author(s).
Références
Pediatr Rheumatol Online J. 2021 Dec 28;19(1):173
pubmed: 34963488
Paediatr Drugs. 2020 Jun;22(3):251-262
pubmed: 32291603
Pediatr Rheumatol Online J. 2019 Aug 22;17(1):57
pubmed: 31438986
Arthritis Rheumatol. 2016 Dec;68(12):3023-3034
pubmed: 27332999
Med Chir Trans. 1897;80:47-60.9
pubmed: 20896907
Int J Rheum Dis. 2019 Sep;22(9):1661-1669
pubmed: 31273940
Pediatr Clin North Am. 2018 Aug;65(4):691-709
pubmed: 30031494
Pediatr Res. 2014 Jan;75(1-2):176-83
pubmed: 24213625
J Pediatr. 2016 Oct;177:19-26
pubmed: 27499217
Annu Rev Public Health. 2007;28:127-43
pubmed: 17222079
Rheumatology (Oxford). 2019 Jan 1;58(1):94-102
pubmed: 30137641
Int J Rheumatol. 2022 Jul 27;2022:1784529
pubmed: 35936656
J Rheumatol. 2016 Sep;43(9):1755-62
pubmed: 27307527
Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7
pubmed: 29357887
J Rheumatol. 2003 Oct;30(10):2275-82
pubmed: 14528529
Int J Rheum Dis. 2022 Nov;25(11):1306-1314
pubmed: 36004429
Asia Pac Allergy. 2022 Jul 18;12(3):e29
pubmed: 35966154
Mod Rheumatol. 2020 Sep;30(5):900-904
pubmed: 31462146
Clin Trials. 2018 Jun;15(3):268-277
pubmed: 29542334
Arthritis Rheumatol. 2014 Jun;66(6):1405-13
pubmed: 24623686
Autoimmun Rev. 2016 Sep;15(9):931-4
pubmed: 27392503
Pediatr Rheumatol Online J. 2017 Apr 11;15(1):23
pubmed: 28399931
Joint Bone Spine. 2014 Mar;81(2):112-7
pubmed: 24210707
Int J Environ Res Public Health. 2021 Aug 06;18(16):
pubmed: 34444082
Ann Med. 2022 Dec;54(1):1839-1850
pubmed: 35786149
Arthritis Rheumatol. 2022 Apr;74(4):553-569
pubmed: 35233993
Clin Exp Rheumatol. 1998 Jan-Feb;16(1):99-101
pubmed: 9543575
Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298
pubmed: 31846042